Chagas chronic cardiomyopathy: Report of two cases in Coahuila, Mexico

José Gerardo Martínez-Tovar, Ildefonso Fernández-Salas, Eduardo A. Rebollar-Téllez

ABSTRACT

Introduction: Chronic cardiomyopathy is a fatal form of the Chagas disease without specific treatment. It is a frequent type of dilated cardiomyopathy usually not recognized by the health team in non-endemic areas. The cases presented here represent the first autochthonous cases of the disease in Coahuila, Mexico.

Case Series: Two cases of dilated cardiomyopathy with positive antibodies to Trypanosoma cruzi are presented, one of them with progressive heart failure and another with conduction disorders.

Conclusion: Even in areas of low endemicity, all cases of dilated cardiomyopathy, Chagas disease should be rule out as one of the etiologies.
Chagas chronic cardiomyopathy: Report of two cases in Coahuila, Mexico

José Gerardo Martínez-Tovar, Ildefonso Fernández-Salas, Eduardo A. Rebollar-Téllez

ABSTRACT

Introduction: Chronic cardiomyopathy is a fatal form of the Chagas disease without specific treatment. It is a frequent type of dilated cardiomyopathy usually not recognized by the health team in non-endemic areas. The cases presented here represent the first autochthonous cases of the disease in Coahuila, Mexico. Case Series: Two cases of dilated cardiomyopathy with positive antibodies to Trypanosoma cruzi are presented, one of them with progressive heart failure and another with conduction disorders. Conclusion: Even in areas of low endemicity, all cases of dilated cardiomyopathy, Chagas disease should be rule out as one of the etiologies.

Keywords: Dilated cardiomyopathy, Chronic cardiomyopathy, Chagas disease, Trypanosoma cruzi
CASE SERIES

Case 1: A sixty-year-old female from Sabinas Coahuila, Mexico who had not visited areas of high endemicity for American trypanosomiasis. She was found to have primary hypothyroidism treated for four years with levothyroxine. Two years before the present admission, she received a blood transfusion due to uterine bleeding. She had been asymptomatic until three years ago when she began to experience progressive dyspnea and edema of lower limbs. The electrocardiogram showed left atrial enlargement and generalized low voltage. The chest X-ray showed grade IV cardiomegaly with a cardiothoracic index 0.57. Basic laboratory tests were within normal limits. Cardiac ultrasound showed severe atrial and moderated ventricular dilatation with an ejection fraction of 35%. gammagram cardiac showed scattered perfusion defects so that cardiac catheterization was performed which was reported as normal. The ventriculography revealed abnormal global and segmental abnormal mobility also severe generalized hypokinesis. Dilated cardiomyopathy was diagnosed initiating treatment with digoxin, furosemide, spironolactone, isosorbide and pravastatin. The patient was admitted into a program for heart transplant protocol. Serological tests performed in our hospital four years later, Enzyme-Linked Immunosorbent Assay (ELISA), indirect hemagglutination and immunofluorescence were reported positive for Chagas disease.

Case 2: A seventy-six-year old male from Múzquiz Coahuila, Mexico. He reported that he had always lived there and had never traveled to endemic areas nor had received blood transfusion. He began his present illness about five years ago when presenting paroxysmal episodes of syncope interpreted as Stock–Adams syndrome secondary to sinus node disease producing symptomatic bradycardia alternating with ventricular premature beats. A permanent pacemaker was placed three years ago. He had been asymptomatic until two years ago began with dyspnea and edema of lower limbs. An evaluation at that time revealed on chest radiography grade III cardiomegaly with a cardio thoracic index 0.57.

The ultrasonography showed cardiac dilatation and left heart ejection fraction of 40%. General laboratory tests were within normal limits. Diagnosis of dilated cardiomyopathy was made and management began with digoxin, furosemide, captopril, isosorbide and acetylsalicylic acid and pravastatin. He had been stable with a functional class II, until March 2011 when he came to our hospital with decompensated heart failure manifested mainly by dyspnea at rest. He was admitted to the intensive care unit to his improvement. At that time, an ELISA test was reported positive for antibodies to T. cruzi. An indirect hemagglutination test was also positive. The patient was discharged with management support for heart failure and diagnosed with chronic Chagas cardiomyopathy. Table 1 gives summary and comparison of clinical and laboratory test results of the two studied cases and Figure 1 shows the corresponding electrocardiograms and chest radiographs.

Table 1: Summary and comparison of clinical and laboratory test results of the two studied cases from the state of Coahuila, Mexico.

<table>
<thead>
<tr>
<th>Gender</th>
<th>Case 1</th>
<th>Case 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>60</td>
<td>76</td>
</tr>
<tr>
<td>Clinical Picture</td>
<td>Cardiac failure</td>
<td>Stock-Adams</td>
</tr>
<tr>
<td>Time of evolution</td>
<td>3 years</td>
<td>5 years</td>
</tr>
<tr>
<td>Functional class</td>
<td>III</td>
<td>II</td>
</tr>
<tr>
<td>NYHA *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>Cardiotoracic index 0.7</td>
<td>Cardiotoracic index 0.57</td>
</tr>
<tr>
<td>Electrocardiogram</td>
<td>Left atrial enlargement and generalized low voltage</td>
<td>Pacemaker</td>
</tr>
<tr>
<td>Ejection fraction</td>
<td>35%</td>
<td>40%</td>
</tr>
<tr>
<td>ELISA **</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>IHA ***</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>IP ****</td>
<td>Positive</td>
<td>Not done</td>
</tr>
</tbody>
</table>

* New York Heart Association
** Enzyme-Linked Immunosorbent Assay
*** Indirect Hemagglutination
**** Indirect Immunofluorescence
DISCUSSION

To the best of our knowledge, these patients are the first two cases of chronic Chagas, cardiomyopathy reported in the state of Coahuila, Mexico. We suggest that they represent autochthonous cases because there is no history of travel or residence in endemic areas and that all their life has been in Coahuila, and based on the clinical histories of patients. We are aware that conclusive evidence is lacking to fully demonstrate the presence of endemic foci of Chagas disease in northern Mexico. Nonetheless, we can put forward several facts that strongly support our suggestion. Firstly, a previous study conducted by our research team showed a seroprevalence of antibodies to T. cruzi in patients with dilated cardiomyopathy to be as high as 21.14% even in areas of low endemicity [13] and these estimates were obtained and confirmed by two different tests [14]. Seroprevalence as such is an estimator at community level and represents some degree of contact with the parasite. Since, only one of the two cases gave a history of recent blood transfusion, and as the disease occurs ten to twenty years after the initial infection, a vectorial transmission is more likely to have occurred. Secondly, in the context of this investigation, we have also shown that two Triatomine species—Triatoma gerstaeckeri and Triatoma rubida— are present in the region. These two species have been reported to harbor T. cruzi parasites [15]. Thirdly, there are reports suggesting that Chagas disease may actually be present in the state of Coahuila since ancient times [14]. Finally, it is important to highlight the urging need to trained health teams in non-endemic areas, because they are not accustomed to the presence of Chagas disease. As this disease represents a potentially emerging treat, it is very important to continue the detection antibodies against T. cruzi in all blood banks, organ as well as the screening in pregnant women and patients with heart diseases. If a systematic surveillance program is established, it would be possible to diagnose acute positive cases in order to undertake specific antiparasitic treatment. In addition, vector ecology and surveillance studies are needed to evaluate the transmission potential of T. cruzi to inhabitants of the region.

CONCLUSION

The diagnosis of Chagas chronic cardiomyopathy is based on the presence of antibodies to Trypanosoma cruzi by serological techniques as Enzyme-Linked Immunosorbent Assay (ELISA), indirect hemagglutination and immunofluorescence in a patient with dilated cardiomyopathy. It is very important to continue to detection of antibodies to T. cruzi in all blood banks and organ donors in general, as well as the screening in pregnant women and patients with heart diseases. The finding of acute positive cases represents an opportunity to undertake specific antiparasitic treatment.

Acknowledgements
The first author is grateful to the support given by Conacyt through a scholarship for doctoral studies # 392195. He also wishes to thank the staff of the General Hospital No. 24 of the Mexican Social Security Institute in Nueva Rosita, Coahuila for the facilities granted.

Author Contributions
José Gerardo Martínez-Tovar – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Ildefonso Fernández-Salas – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Eduardo A. Rebollar-Téllez – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Figure 1: Electrocardiogram and chest X-ray. (A) Electrocardiogram with left atrial enlargement and generalized low voltage of Case 1. (C) chest X-rays with grade IV cardiomegaly and cardiothoracic index 0.7. (B) electrocardiogram with a pacemaker spikes, (D) chest X-ray with grade III cardiomegaly and cardiothoracic index 0.57 of Case 2.
REFERENCES


ABOUT THE AUTHORS


**Jose Gerardo Martínez-Tovar**

is Head of Internal Medicine Department at Hospital General de Zona No 24 “Dr. Jesus Felix Oyervides Pinales” of the Instituto Mexicano del Seguro Social in Nueva Rosita, Coahuila México. He earned the Medical Degree from Universidad Autónoma de Nuevo León and Internal Medicine Speciality from Secretaria de Salud in Monterrey, México. He is a doctoral student at Medical Entomology Laboratory in the Biology School of Universidad Autónoma de Nuevo León. He has published three research papers in national and international academic journals. His research interests include Chagas disease, leishmaniasis, dengue fever and insects of medical importance. He intends to pursue a postdoc in new treatments and diagnosis tools of Chagas disease in future.

**Ildefonso Fernández-Salas**

is Director of Regional Center for Public Health at National Institute of Public Health in Tapachula, Chiapas, Southern Mexico. He earned the doctoral degree (Medical Entomology, PhD) from The Uniformed Services University of the Health Sciences/Bethesda, Maryland-USA. He has published 78 research papers in national and international academic journals and authored 2. His research interests include Epidemiology and control on dengue fever, malaria, and West Nile Virus mosquito vectors.

**Eduardo A. Rebollar-Téllez**

is Lecturer/Researcher at Medical Entomology Lab, Department of Invertebrate Zoology, Biological Sciences Faculty/ Autonomous University of Nuevo Leon/ Monterrey / Mexico). He earned the undergraduate degree (BSc Biology) from the Biological Sciences Faculty/ Autonomous University of Nuevo Leon, a Master degree in Medical Entomology (Biological Sciences Faculty/Autonomous University of Nuevo Leon) and a PhD from the Centre for Applied Entomology and Parasitology, School of Biological Sciences, Keele University, Staffordshire, United Kingdom. He has been granted several scholarships from Conacyt (Mexico), The Wellcome Trust (UK), WHO/ TDR (Switzerland). John D. & Catherine T. MacArthur Foundation (USA), EULEISH/ International Centre for Engineering and Biotechnology ICBEG (Trieste, Italy) and the Japan International Cooperation Agency (JICA) (Tokyo, Japan). He has published 43 research papers in national and international academic journals and authored 2 book chapters. His research interests include the epidemiology and dynamics of transmission of leishmaniasis, Chagas disease and other zoonotic diseases. He intends to pursue a postdoc or sabbatical leave to further strengthen his career as a medical entomologist.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Mentored Review Articles (MRA)
Our academic program “Mentored Review Article” (MRA) gives you a unique opportunity to publish papers under mentorship of international faculty. These articles are published free of charges.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.